

ABSTRACT

An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile
5 acid transport (IBAT inhibitor compound) and a therapeutically acceptable carrier
characterised in that the formulation is designed to deliver the IBAT inhibitor compound in
the ileum. The IBAT inhibitor compound can also be administered in combination with a
bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor
10 compounds, such as for instance diarrhoea. The bile acid binder may be formulated for
colon release.